Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)

Summary

This is a multicenter,randomized,double-blind, placebo-controlled, phase 2 study designed to evaluate the safety, tolerability and efficacy of a continuous rate infusion (CRI) of IV varespladib followed by transition to the oral dosage form, varespladib-methyl, concurrently with SOC, in participants bitten by venomous snakes. Note: Funding Source - FDA-OOPD

Timeline

Start

2023-05-30

Primary completion

2024-11-28

Completion

2025-02-24

Publications

• Woliver C, Kastenholz V, Southern C, Odunayo A, Schaer M, Allen-Durrance A. Phospholipase A2 inhibitor may shorten the duration of clinical signs in the treatment of neurotoxicity caused by eastern coral snake (Micrurus fulvius) envenomation in 3 dogs. J Am Vet Med Assoc. 2025 Jul 30;263(12):1-7. doi: 10.2460/javma.25.04.0275. Print 2025 Dec 1.

Drugs

Indications